Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by SABBOBCATon Dec 05, 2019 6:36pm

75 Views

Post# 30426999

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I am getting envious

My biggest fear would be that management is trying to hype the egrifta potential to do a raise for the oncology platform. When in reality they doubt the ability to get a patent extension from the FDA.

SABBOBCAT wrote: Also, why isn't Grinspoon listed as a Scientific consultant when the oncologists are? I get that the platform may ba a huge value driver down the road, but what about the man that got the company here? Heads ought to Rolle for that.
SABBOBCAT wrote: It is ridiculous. If management gets paid for his work it would be a huge mistake. The BOD needs to recognize and acknowledge that. Give Grinspoon the options that management has come to expect regardless of performance. Grinspoon is the only reason there is a bright spot on the horizon following the trogarzo sales disappointment. Luc got his options for saving the company. He should not be entitled to more of them for lackluster performance. Give credit where it's due!
palinc2000 wrote: Sabbocoat
I was flabbergasted when I found out that TH did not even supply Egrifta free of charge,,,,,and when Grinspoon mentioned in his report that apart from supplyng Egrifta at a reduced price TH had NO input whatsoever during the trial

I still have a bad feeling about Grinspoon not being physically present at the R&D Day and moreover that he had to step away from the teleconference early

This does not indicate imo a very friendly relation....However I have no direct knowledge